Research Backs Up Ravulizumab's Safety and Effectiveness in IgA Nephropathy Patients.

Published Date: 17 Dec 2023

By week 26, the proteinuria reduction in the ravulizumab group was 40 points3 percent, while the placebo group experienced a reduction of 10 points9 percent. This indicates that ravulizumab is an effective treatment for patients with IgA Nephropathy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot